サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：頭頸部がん治療薬の市場規模、シェア＆動向分析レポート：治療タイプ別（化学療法、免疫療法、標的療法）、投与経路別、流通チャネル別、地域別、セグメント別予測、2022年～2030年
市場調査レポート
商品コード
1170875

頭頸部がん治療薬の市場規模、シェア＆動向分析レポート：治療タイプ別（化学療法、免疫療法、標的療法）、投与経路別、流通チャネル別、地域別、セグメント別予測、2022年～2030年

Head And Neck Cancer Therapeutics Market Size, Share & Trends Analysis Report By Therapy Type (Chemotherapy, Immunotherapy, Targeted Therapy), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2022 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 120 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
頭頸部がん治療薬の市場規模、シェア＆動向分析レポート：治療タイプ別（化学療法、免疫療法、標的療法）、投与経路別、流通チャネル別、地域別、セグメント別予測、2022年～2030年
出版日: 2022年11月03日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

頭頸部がん治療薬市場の成長と動向

Grand View Research, Inc.の新しいレポートによると、世界の頭頸部がん治療薬の市場規模は2030年までに35億米ドルに達すると予測されています。同市場は、2022年から2030年にかけてCAGR12.5％で拡大すると予測されています。頭頸部がん（HNC）の診断と治療における進歩の増加は、費用対効果が高く、外科手術よりも対象が特定されるため、市場成長を促進すると予想されます。さまざまな種類のHNCの有病率の上昇と老年人口の増加が、市場の主な促進要因となっています。

がん研究所によると、2021年には米国で約54,000人が異なるタイプのHNCと診断され、約11,000人が死亡したと報告されています。大量のアルコール摂取、長時間の日光への露出、エプスタインバーウイルス（EBV）などのがんの原因となるウイルス感染、タバコ消費などは、世界中でさまざまな頭頸部がんの発生率を高める主要因とされています。

また、国連によると、2020年には全世界で60歳以上の高齢者が約7億2,700万人いると推定されています。また、老年人口は2020年の9.3%から2050年には16%に増加することが予想されています。加齢により免疫力が低下し、さまざまな種類のHNCにかかりやすくなるため、結果として病気の治療のための治療薬の需要が高まります。

さらに、新規標的薬の開発や集学的治療アプローチのための研究開発活動の増加は、頭頸部がんに苦しむ患者の生存率向上につながると期待されています。例えば、Merck/Debiopharm社のXevinapantは、現在、扁平上皮頭頸部がんの治療薬として第III相臨床試験が実施されています。また、米国FDAからブレークスルーセラピー（画期的治療法）の指定を受けています。

また、支援的な償還政策も市場成長の原動力になると予想されます。複数の組織が、患者やその介護者が医薬品を購入する際の経済的支援を行っています。例えば、2022年7月、英国コロンビアがんは、カペシタビン、カルボプラチン、セツキシマブ、シスプラチン、ドセタキセル、ドキソルビシン、フルオロウラシル、ロイコボリンカルシウムを給付薬剤リストに含めました。このリストに含まれる薬剤は、承認された適応症に対する払い戻しに適用されます。

頭頸部がん治療薬市場レポートハイライト

治療タイプ別では、支持的な償還政策の存在と、頭頸部がん疾患に対する有効な治療法としての免疫療法薬の高い有効性により、免疫療法セグメントが2021年に最大の市場シェアを占めた

投与経路別では、経口投与セグメントが予測期間中に最も急速に成長すると予想されます。これは、希少疾患患者におけるこの投与経路に関連する高い安全性、有効性、忍容性に起因するものである

流通チャネル別では、小売・専門薬局セグメントが2021年の市場を独占しました。この優位性は、腫瘍医が専門薬局を好むことに起因していると考えられます。腫瘍医はしばしば専門薬局を必要とするため、豊富な治療知識で治療計画をサポートし、管理負担から解放することができます

アジア太平洋地域は、予測期間中に最も急成長している地域であると予想されます。同地域の成長の背景には、同地域への新製品の参入が挙げられます。例えば、2020年にNMPAは、メルク・アンド・カンパニー・インクが開発したERBITUX（セツキシマブ）を、中国の頭頸部がん患者の治療薬として承認した

目次

第1章 調査手法と範囲

  • 市場セグメンテーション
    • セグメントの範囲
    • 地域範囲
  • 調査手法
  • 情報調達
    • 購入したデータベース
    • GVRの内部データベース
    • 二次情報
    • 1次調査
    • 1次調査内容
  • 情報またはデータ分析
    • データ分析モデル
  • 市場の策定と検証
  • モデルの詳細
    • コモディティフロー分析
      • アプローチ1：コモディティフローアプローチ
      • アプローチ2：ボトムアップアプローチを使用した国ごとの市場推定
      • アプローチ3：トップダウンアプローチを使用した国ごとの市場推定
  • 世界市場：CAGR計算
  • 調査の仮定
  • 主なKoL応答
  • 市場シェアの計算
  • 二次情報一覧
  • 目的
  • 略語一覧

第2章 エグゼクティブサマリー

  • 市場概要

第3章 頭頸部がん治療薬市場- 業界の展望

  • 市場系列の見通し
    • 親市場系統の見通し
    • 関連/補助的な市場の見通し
  • 浸透と成長の見通しのマッピング
  • 市場力学
    • 市場促進要因分析
      • 頭頸部がんの有病率の増加
      • 高齢者人口の増加
      • 研究開発の増加とパイプライン製品の強力な存在感
      • 支援的な償還ポリシーと病気に対する意識の高まり
    • 市場抑制要因分析
      • 安全性と有効性に関するデータの不足
      • 高額な治療費
  • 頭頸部がん治療市場分析ツール
    • 業界分析- ポーターズ
    • SWOT分析、要因別（政治と法律、経済と技術）
      • 政治と法律
      • 経済と社会
      • 技術
  • 償還と規制のシナリオ
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • MEA
  • 主要取引と戦略的提携
    • 新製品の発売
    • 取得
    • 拡張
    • パートナーシップ
  • パイプライン分析

第4章 頭頸部がん治療薬市場分析：治療タイプの範囲、2018年から2030年（収益、100万米ドル）

  • 頭頸部がん治療薬市場：治療タイプの変動分析
  • 化学療法
  • 免疫療法
  • 標的療法

第5章 頭頸部がん治療薬市場分析：投与範囲の経路、2018年から2030年（収益、100万米ドル）

  • 頭頸部がん治療薬市場：投与経路の変動分析
  • 注射剤
  • 経口

第6章 頭頸部がん治療薬市場分析：流通チャネルの範囲、2018年から2030年（収益、100万米ドル）

  • 頭頸部がん治療薬市場：流通チャネルの変動分析
  • 小売および専門薬局
  • 病院薬局
  • オンライン薬局

第7章 頭頸部がん治療薬市場分析、地域範囲、2017年から2030年、（収益、100万米ドル）

  • 2021年と2030年の地域別市場シェア分析
    • 北米
      • 米国
      • カナダ
    • 欧州
      • 英国
      • ドイツ
      • フランス
      • イタリア
      • スペイン
    • アジア太平洋地域
      • 日本
      • 中国
      • インド
      • オーストラリア
      • 韓国
    • ラテンアメリカ
      • ブラジル
      • メキシコ
      • アルゼンチン
    • 中東およびアフリカ（MEA）
      • 南アフリカ
      • サウジアラビア
      • 南アフリカ

第8章 頭頸部がん治療薬市場：競合分析

  • 主要な市場参入企業別最近の動向と影響分析
    • アンゾフのマトリクス
  • 会社の分類
    • イノベーター
      • 市場の差別化要因
  • ベンダー情勢
    • 主要なディストリビューターとチャネルパートナーのリスト
    • 主要顧客
    • 主要企業の市場シェア分析、2020年
  • 公開会社
    • 会社の市況分析
    • 競合ダッシュボード分析
  • 非公開会社
    • 主要新興企業一覧
  • Regional Network Map
  • 企業プロファイル
    • Eli Lilly and Company
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • Sanofi
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • Merck &Co., Inc.
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • Clingen Group plc.
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • Bristol-Mayers Squibb Company
      • 会社概要
      • アフィメトリックス
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • Takeda Pharmaceutical Company Limited
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • Teva Pharmaceutical Industries Ltd
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • F. Hoffmann-La Roche Ltd.
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
図表

List of Tables

  • TABLE 1 List of Secondary Sources
  • TABLE 2 List of Abbreviations
  • TABLE 3 Global Head and Neck Cancer Therapeutics Market, By Region, 2018 - 2030 (USD Million)
  • TABLE 4 Global Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 5 Global Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 6 Global Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 7 North America Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 8 North America Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 9 North America Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 10 U.S. Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 11 U.S. Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 12 U.S. Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 13 Canada Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 14 Canada Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 15 Canada Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 16 Europe Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 17 Europe Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 18 Europe Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 19 Germany Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 20 Germany Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 21 Germany Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 22 U.K. Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 23 U.K. Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 24 U.K. Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 25 France Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 26 France Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 27 France Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 28 Italy Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 29 Italy Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 30 Italy Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 31 Spain Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 32 Spain Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 33 Spain Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 34 Asia Pacific Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 35 Asia Pacific Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 36 Asia Pacific Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 37 Japan Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 38 Japan Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 39 Japan Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 40 China Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 41 China Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 42 China Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 43 India Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 44 India Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 45 India Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 46 South Korea Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 47 South Korea Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 48 South Korea Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 49 Australia Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 50 Australia Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 51 Austalia Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 52 Latin America Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 53 Latin America Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 54 Latin America Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 55 Brazil Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 56 Brazil Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 57 Brazil Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 58 Mexico Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 59 Mexico Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 60 Mexico Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 61 Argentina Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 62 Argentina Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 63 Argentina Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 64 Middle East & Africa Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 65 Middle East & Africa Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 66 Middle East & Africa Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 67 Saudi Arabia Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 68 Saudi Arabia Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 69 Saudi Arabia Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 70 South Africa Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 71 South Africa Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 72 South Africa Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 73 UAE Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 74 UAE Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 75 UAE Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • FIG. 1 Head and neck cancer therapeutics market segmentation
  • FIG. 2 Market research process
  • FIG. 3 Data triangulation techniques
  • FIG. 4 Primary research pattern
  • FIG. 5 Market research approaches
  • FIG. 6 Value-chain-based sizing & forecasting
  • FIG. 7 QFD modelling for market share assessment
  • FIG. 8 Market formulation & validation
  • FIG. 9 Head and neck cancer therapeutics market snapshot
  • FIG. 10 Parent market outlook
  • FIG. 11 Related/ancillary market outlook, revenue, 2021, (USD Million)
  • FIG. 12 Penetration and growth prospect mapping
  • FIG. 13 Head and neck cancer therapeutics market driver impact
  • FIG. 14 Head and neck cancer therapeutics market restraint impact
  • FIG. 15 SWOT analysis, by factor (political & legal, economic, and technological)
  • FIG. 16 Industry Analysis - Porter's
  • FIG. 17 Strategy mapping
  • FIG. 18 Head and neck cancer therapeutics market: Therapy type outlook and key takeaways
  • FIG. 19 Head and neck cancer therapeutics market: Therapy type movement analysis & market share 2021 & 2030
  • FIG. 20 Chemotherapy market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 21 Immunotherapy market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 22 Targeted therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 23 Head and neck cancer therapeutics market: Route of Administration outlook and key takeaways
  • FIG. 24 Head and neck cancer therapeutics market: Route of administration movement analysis & market share 2021 & 2030
  • FIG. 25 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 26 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 27 Head and neck cancer therapeutics market: Distribution Channel outlook and key takeaways
  • FIG. 28 Head and neck cancer therapeutics market: Distribution Channel movement analysis & market share 2021 & 2030
  • FIG. 29 Retail & specialty pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 30 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 31 Online pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 32 Head and neck cancer therapeutics: Regional outlook and key takeaways
  • FIG. 33 Regional outlook, 2021 & 2030
  • FIG. 34 North America
  • FIG. 35 North America market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 36 U.S.
  • FIG. 37 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 38 Canada
  • FIG. 39 Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 40 Europe
  • FIG. 41 Europe market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 42 U.K.
  • FIG. 43 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 44 Germany
  • FIG. 45 Germany market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 46 France
  • FIG. 47 France market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 48 Italy
  • FIG. 49 Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 50 Spain
  • FIG. 51 Spain market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 52 Asia Pacific
  • FIG. 53 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 54 Japan
  • FIG. 55 Japan market estimates and forecast, 2018 - 2030(USD Million)
  • FIG. 56 China
  • FIG. 57 China market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 58 India
  • FIG. 59 India market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 60 South Korea
  • FIG. 61 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 62 Australia
  • FIG. 63 Australia market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 64 Latin America
  • FIG. 65 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 66 Brazil
  • FIG. 67 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 68 Mexico
  • FIG. 69 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 70 Argentina
  • FIG. 71 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 72 Middle East & Africa
  • FIG. 73 MEA market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 74 South Africa
  • FIG. 75 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 76 Saudi Arabia
  • FIG. 77 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 78 UAE
  • FIG. 79 UAE market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 80 Market differentiators
  • FIG. 81 Key company market share analysis, 2021
  • FIG. 82 Company market position analysis
  • FIG. 83 Competitive dashboard analysis
  • FIG. 84 Regional network map
目次
Product Code: GVR-2-68038-125-2

Head And Neck Cancer Therapeutics Market Growth & Trends:

The global head and neck cancer therapeutics market size is expected to reach USD 3.5 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 12.5% from 2022 to 2030. Increasing advancements in the diagnosis and treatment of head and neck cancer (HNC) are anticipated to propel market growth, as they are cost-effective and more specific to target over surgeries. The increasing prevalence of different types of HNCs and the growing geriatric population are major drivers of the market.

According to the Cancer Research Institute, in 2021, approximately 54,000 people were diagnosed with different types of HNC and about 11,000 deaths were reported in the U.S. Heavy alcohol consumption, prolonged sun exposure, cancer-causing viral infection such as Epstein-Barr virus (EBV) and tobacco consumption are some of the major factors contribute to rising incidence of various head and neck cancers worldwide.

Furthermore, according to the United Nations, it was estimated that, in 2020, there were around 727 million people aged 60 years and above worldwide. In addition, the geriatric population is expected to increase from 9.3% in 2020 to 16% in 2050. Aging weakens the immune system and makes people susceptible to different types HNCs, consequently, increasing the demand for therapeutic drugs for the treatment of disease.

Moreover, an increase in R&D activities for the development of novel targeted drugs and a multidisciplinary therapeutic approach is expected to lead to an increased survival rate of patients suffering from head and neck cancers. For instance, Merck/Debiopharm's Xevinapant is currently in phase III clinical trials for the treatment of squamous head and neck cancer. It has received breakthrough therapy designation from the U.S. FDA.

Supportive reimbursement policies are also expected to drive market growth. Several organizations provide financial assistance to patients and their caregivers for purchasing medicines. For instance, in July 2022, British Colombia Cancer included Capecitabine, Carboplatin, Cetuximab, Cisplatin, Docetaxel, Doxorubicin, Fluorouracil, and Leucovorin Calcium in their benefit drug list. Drugs included in this list are applicable for reimbursement for approved indications.

Head And Neck Cancer Therapeutics Market Report Highlights:

  • By therapy type, the immunotherapy segment held the largest market share in 2021 due to the presence of supportive reimbursement policies and the higher efficacy of immunotherapy drugs as an effective treatment for head and neck cancer diseases
  • By route of administration, the oral segment is expected to be the fastest-growing segment during the forecast period. This can be attributed to the high safety, efficacy, and tolerability associated with this route of administration among rare disease patients
  • By distribution channel, the retail and specialty pharmacy segment dominated the market in 2021. This dominance can be attributed to the preference of oncologists for specialty pharmacies. Oncologists often need specialty pharmacies so that with extensive therapeutic knowledge, they can support treatment plans and relieve them from the administrative burden
  • Asia Pacific is expected to be the fastest-growing region during the forecast period. The growth of the region can be attributed to the entry of new products into the region. For instance, in 2020, NMPA approved ERBITUX (Cetuximab) developed by Merck and Co., Inc., to treat patients with head and neck cancer in China

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation
    • 1.1.1 Segment scope
    • 1.1.2 Regional scope
    • 1.1.3 Estimates and Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details of Primary Research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach 1: Commodity flow approach
      • 1.6.1.2 Approach 2: Country wise market estimation using bottom up approach
      • 1.6.1.3 Approach 3: Country wise market estimation using top down approach
  • 1.7 Global Market: CAGR Calculation
  • 1.8 Research Assumptions
  • 1.9 Key KoL Responses
  • 1.10 Market Share Calculations
  • 1.11 List of Secondary Sources
  • 1.12 Objectives
    • 1.12.1 Objective 1:
    • 1.12.2 Objective 2:
  • 1.13 List of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Market Summary

Chapter 3 Head and Neck Cancer Therapeutics Market - Industry Outlook

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Lineage Outlook
    • 3.1.2 Related/Ancillary Market Outlook
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Market Dynamics
    • 3.3.1 Market Drivers Analysis
      • 3.3.1.1 Increasing prevalence of head and neck cancers
      • 3.3.1.2 Rising geriatric population
      • 3.3.1.3 Increasing R&D and strong presence of pipeline product
      • 3.3.1.4 Supportive reimbursment policies and rising awareness about disease
    • 3.3.2 Market Restraint Analysis
      • 3.3.2.1 Paucity of data related to safety and efficacy
      • 3.3.2.2 High cost of treatments
  • 3.4 Head and Neck Cancer Therapeutics Market Analysis Tools
    • 3.4.2 Industry Analysis - Porter's
    • 3.4.3 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
      • 3.4.3.1 Political and Legal
      • 3.4.3.2 Economic & Social
      • 3.4.3.3 Technological
  • 3.5 Reimbursement & Regulatory Scenario
    • 3.5.1 North America
    • 3.5.1 Europe
    • 3.5.2 Asia Pacific
    • 3.5.3 Latin America
    • 3.5.4 MEA
  • 3.6 Major Deals & Strategic Alliances
    • 3.6.1 New Product Launch
    • 3.6.2 Acquisition
    • 3.6.3 Expansion
    • 3.6.4 Partnerships
  • 3.7 Pipeline analysis

Chapter 4 Head and Neck Cancer Therapeutics Market Analysis: Therapy Type Scope, 2018 - 2030 (Revenue, USD Million)

  • 4.1 Head and Neck Cancer Therapeutics Market: Therapy Type Movement Analysis
  • 4.2 Chemotherapy
    • 4.2.1 Chemotherapy market estimates and forecast, 2018 - 2030 (USD million)
  • 4.3 Immunotherapy
    • 4.3.1 Immunotherapy market estimates and forecast, 2018 - 2030 (USD million)
  • 4.4 Targeted Therapy
    • 4.4.1 Targeted therapy market estimates and forecast, 2018 - 2030 (USD million)

Chapter 5 Head and Neck Cancer Therapeutics Market Analysis: Route of Administration Scope, 2018 - 2030 (Revenue, USD Million)

  • 5.1 Head and Neck Cancer Therapeutics Market: Route of Administration Movement Analysis
  • 5.2 Injectables
    • 5.2.1 Injectables market estimates and forecast, 2018 - 2030 (USD million)
  • 5.3 Oral
    • 5.3.1 Oral market estimates and forecast, 2018 - 2030 (USD million)

Chapter 6 Head and Neck Cancer Therapeutics Market Analysis: Distribution Channel Scope, 2018 - 2030 (Revenue, USD Million)

  • 6.1 Head and Neck Cancer Therapeutics Market: Distribution Channel Movement Analysis
  • 6.2 Retail & Specialty Pharmacies
    • 6.2.1 Retail & specialty pharmacies market estimates and forecast, 2018 - 2030 (USD million)
  • 6.3 Hospital Pharmacies
    • 6.3.1 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD million)
  • 6.4 Online Pharmacies
    • 6.4.1 Online pharmacies market estimates and forecast, 2018 - 2030 (USD million)

Chapter 7 Head and Neck Cancer Therapeutics Market Analysis, Regional Scope, 2017-2030, (Revenue, USD Million)

  • 7.1 Market Share Analysis by Regional, 2021 & 2030
    • 7.1.1 North America
      • 7.1.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.1.2 U.S.
      • 7.1.1.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.1.3 Canada
      • 7.1.1.3.1 Canada market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.2 Europe
      • 7.1.2.1 Europe market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.2 U.K.
      • 7.1.2.2.1 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.3 Germany
      • 7.1.2.3.1 Germany market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.4 France
      • 7.1.2.4.1 France market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.5 Italy
      • 7.1.2.5.1 Italy market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.6 Spain
      • 7.1.2.6.1 Spain market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.3 Asia Pacific
      • 7.1.3.1 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.2 Japan
      • 7.1.3.2.1 Japan market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.3 China
      • 7.1.3.3.1 China market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.4 India
      • 7.1.3.4.1 India market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.5 Australia
      • 7.1.3.5.1 Australia market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.6 South Korea
      • 7.1.3.6.1 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.4 Latin America
      • 7.1.4.1 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.4.2 Brazil
      • 7.1.4.2.1 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.3 Mexico
      • 7.1.3.3.1 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.4 Argentina
      • 7.1.3.4.1 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.5 Middle East and Africa (MEA)
      • 7.1.8.1 Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.8.2 South Africa
      • 7.1.8.2.1 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.3 Saudi Arabia
      • 7.1.3.3.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.4 South Africa
      • 7.1.3.4.1 South Africa market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8 Head and Neck Cancer Therapeutics Market: Competitive Analysis

  • 8.1 Recent Developments and Impact Analysis, by Key Market Participants
    • 8.1.1 Ansoff matrix`
  • 8.2 Company Categorization
    • 8.2.1 Innovators
      • 8.2.2.1 Market Differentiators
  • 8.3 Vendor Landscape
    • 8.3.1 List of Key Distributors And Channel Partners
    • 8.3.2 Key Customers
    • 8.3.3 Key Company Market Share Analysis, 2020
  • 8.4 Public Companies
    • 8.4.1 Comapany Market Position analysis
    • 8.4.2 Competitive dashboard analysis
  • 8.5 Private Companies
    • 8.5.1 List of Key Emerging Companies
  • 8.6 Regional Network Map
  • 8.8 Company Profiles
    • 8.8.1 Eli Lilly and Company
      • 8.8.1.1 Company overview
      • 8.8.1.2 Financial performance
      • 8.8.1.3 Product benchmarking
      • 8.8.1.4 Strategic initiatives
    • 8.8.2 Sanofi
      • 8.8.2.1 Company overview
      • 8.8.2.2 Financial performance
      • 8.8.2.3 Product benchmarking
      • 8.8.2.4 Strategic initiatives
    • 8.8.3 Merck & Co., Inc.
      • 8.8.3.1 Company overview
      • 8.8.3.2 Financial performance
      • 8.8.3.3 Product benchmarking
      • 8.8.3.4 Strategic initiatives
    • 8.8.4 Clingen Group plc.
      • 8.8.4.1 Company overview
      • 8.8.4.2 Financial performance
      • 8.8.4.3 Product benchmarking
      • 8.8.4.4 Strategic initiatives
    • 8.8.5 Bristol-Mayers Squibb Company
      • 8.8.5.1 Company overview
      • 8.8.5.2 Affymetrix
      • 8.8.5.3 Company overview
      • 8.8.5.4 Financial performance
      • 8.8.5.5 Product benchmarking
      • 8.8.5.6 Strategic initiatives
    • 8.8.6 Takeda Pharmaceutical Company Limited
      • 8.8.6.1 Company overview
      • 8.8.6.2 Financial performance
      • 8.8.6.3 Product benchmarking
      • 8.8.6.4 Strategic initiatives
    • 8.8.7 Teva Pharmaceutical Industries Ltd
      • 8.8.7.1 Company overview
      • 8.8.7.2 Financial performance
      • 8.8.7.3 Product benchmarking
      • 8.8.7.4 Strategic initiatives
    • 8.8.8 F. Hoffmann-La Roche Ltd.
      • 8.8.8.1 Company overview
      • 8.8.8.2 Financial performance
      • 8.8.8.3 Product benchmarking
      • 8.8.8.4 Strategic initiatives